Urokinase receptor

Function

Urokinase receptor or Urokinase plasminogen activator surface receptor or CD87 (uPAR) plays an important role in migration of T cells^[1]. uPAR is a GPI-anchored membrane protein. It triggers cell signalling and regulates gene expression within the cell

Disease

uPAR can control the shift between tutor dormancy and proliferation to form metastasis^[2]

Relevance

Elevated levels of soluble uPAR are associated with kidney disease^[3]. uPAR which is expressed at high levels in malignant tutors is unattractive target for treatment of cancer^[4]. uPAR activity in cancer cells may counteract the activity of anticancer drugs^[5].

Structural highlights

This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

ReferencesReferences

↑ Nykjaer A, Møller B, Todd RF 3rd, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994 Jan 15;152(2):505-16 PMID:8283034
↑ Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017 Aug 24;7(1):9388. PMID:28839232 doi:10.1038/s41598-017-10062-1
↑ Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. PMID:26539835 doi:10.1056/NEJMoa1506362
↑ Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022 Mar 18;20(1):135. PMID:35303878 doi:10.1186/s12967-022-03329-3
↑ Gonias SL, Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015 Jul 27;6:154. PMID:26283964 doi:10.3389/fphar.2015.00154

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky

[1] Nykjaer A, Møller B, Todd RF 3rd, Christensen T, Andreasen PA, Gliemann J, Petersen CM. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994 Jan 15;152(2):505-16 PMID:8283034

[2] Mauro CD, Pesapane A, Formisano L, Rosa R, D'Amato V, Ciciola P, Servetto A, Marciano R, Orsini RC, Monteleone F, Zambrano N, Fontanini G, Servadio A, Pignataro G, Grumetto L, Lavecchia A, Bruzzese D, Iaccarino A, Troncone G, Veneziani BM, Montuori N, Placido S, Bianco R. Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Sci Rep. 2017 Aug 24;7(1):9388. PMID:28839232 doi:10.1038/s41598-017-10062-1

[3] Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. PMID:26539835 doi:10.1056/NEJMoa1506362

[4] Zhai BT, Tian H, Sun J, Zou JB, Zhang XF, Cheng JX, Shi YJ, Fan Y, Guo DY. Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer. J Transl Med. 2022 Mar 18;20(1):135. PMID:35303878 doi:10.1186/s12967-022-03329-3

[5] Gonias SL, Hu J. Urokinase receptor and resistance to targeted anticancer agents. Front Pharmacol. 2015 Jul 27;6:154. PMID:26283964 doi:10.3389/fphar.2015.00154

[1]

[2]

[3]

[4]

[5]